AstraZeneca’s efforts to combine two of its top cancer drugs – Imfinzi and Lynparza – has been rewarded with positive results in an endometrial cancer study that could lead to regulatory ...

The European Commission has cleared AZ's PD-L1 inhibitor Imfinzi (durvalumab) alongside PARP inhibitor Lynparza (olaparib) for patients with primary advanced or recurrent endometrial cancer with ...

Imfinzi recommended for approval in European Union for the treat of adults with limited-stage small cell lung cancer ...

AstraZeneca Plc (NASDAQ:AZN) reported fourth-quarter sales of $14.89 billion, up 18% year over year (+19% at constant ...

Meanwhile, Imfinzi (durvalumab) has been recommended for use in combination ... The latest recommendations come less than two weeks after the company’s Lynparza (olaparib) was recommended by NICE to ...

AstraZeneca’s (AZ) Imfinzi (durvalumab) has been recommended by the European Medicines Agency’s human medicines committee to treat an aggressive form of lung cancer. The Committee for Medicinal ...

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended AstraZeneca's Imfinzi (durvalumab) for approval in the European Union (EU) as a single agent for ...

Imfinzi recommended for approval in the EU by CHMP as first and only immunotherapy for limited-stage small cell lung cancer Recommendation based on ADRIATIC Phase III trial results which ...

AstraZeneca’s (AZN) Imfinzi has been recommended for approval in the European Union, EU, as monotherapy for the treatment of adults with limited-stage small cell lung cancer, LS-SCLC ...